Prognostic modeling of myxoid liposarcoma by gene expression and histopathology with focus on tumor immunity.

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K16408
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: The University of Tokyo
• Principal Investigator: Takashi Kamatani 東京大学, 大学院理学系研究科(理学部), 特任助教 (90645764)
• Project Period (FY): 2020-04-01 – 2022-03-31
• Keywords: がん免疫 / 脂肪肉腫 / 遺伝子発現

Outline of Final Research Achievements

This study aims to elucidate tumor immunity in myxoid liposarcoma (ML) based on gene expression, histopathology and whole exome sequencing data so as not only to predict prognosis but also the response for cancer immunotherapy drugs. We combined gene expression data, pathology images, and whole exon sequencing data of ML to extract prognostic features. I published several papers using the analysis methods developed in this study and was invited as a guest speaker to conferences.

Free Research Field

がん免疫

Academic Significance and Societal Importance of the Research Achievements

近年、本邦でもがん免疫療法が開始されたが、奏功率は低く、有効な患者を予測する解析手法の探索が進んでいる。本研究により、粘液型脂肪肉腫の腫瘍免疫を遺伝子発現、DNA変異データと病理組織から解明することで、予後予測のみならず、将来のがん免疫療法の薬剤応答への評価指標として期待ができる。また今回開発した解析手法を、その他の別種のがんにも適応することで、従来とは異なった治療奏効マーカーの発見につながると考える。